Paroxetine — Non-Hormonal Vasomotor Symptom Support
A non-hormonal SSRI option used in selected menopausal patients for vasomotor symptom support when hormone therapy is not preferred or not appropriate.
Paroxetine
A selective serotonin reuptake inhibitor used in selected patients for menopausal vasomotor symptom support when a non-hormonal approach is desired.
Tamoxifen Consideration
Paroxetine is generally avoided in patients taking tamoxifen because CYP2D6 inhibition may reduce tamoxifen activation.
| Protocol | Frequency | Notes |
|---|---|---|
| 10 mg | Daily | Individualized compounding protocol per prescriber direction |
A low-dose paroxetine mesylate 7.5 mg capsule is the FDA-approved branded menopause-specific product; individualized regimens may differ by clinical plan.
- Used when a non-hormonal option is preferred for vasomotor symptoms.
- Review the full medication list before starting because serotonergic interactions matter.
- Avoid or use with great caution in patients taking tamoxifen because paroxetine can reduce tamoxifen efficacy.
- Monitor for mood changes, suicidal thinking, bleeding risk, and serotonin-related adverse effects early in treatment.
Paroxetine is an SSRI that alters central serotonin signaling. This can reduce menopausal hot flash frequency and severity in selected patients even though it is not a hormone therapy.
- Concomitant MAOI use or use within required washout windows
- Use with pimozide or thioridazine
- Known hypersensitivity to paroxetine
- Caution with tamoxifen because of CYP2D6 inhibition
Common adverse effects: Nausea, somnolence, insomnia, sweating, sexual side effects, and headache may occur.
- Store at 20°C to 25°C (68°F to 77°F). Protect from light and humidity.
- The medicine should be fine for 5 days from the shipping date at temperatures up to 105 degrees Fahrenheit.
Is this hormone therapy?
No. Paroxetine is a non-hormonal option used in selected patients for vasomotor symptom support.
Why does tamoxifen matter?
Paroxetine can inhibit CYP2D6 and may reduce tamoxifen’s conversion to its active metabolite.
Partner with Genesis Compounding
A 503A-licensed compounding partner built for telehealth and physician practice workflows. Download your onboarding documents below to get started.
Fax completed forms to 385-855-1221 or email pharmacy@genesiscompounding.com